Furthermore, identification of cholesterol as an agonist of ERRα and a regulator of ERRα target gene expression, and proliferation in ER+ and TNBC cells, also has relevance to other subtypes of breast cancer, like the human epidermal growth factor receptor 2 positive (HER2+) subtype, and other cancer types such as prostate, ovary, and colorectal cancers, where ERRα is overexpressed and known to play a pathological role. This evidence concerns the gene ESR1 and colorectal cancer.